Form D · Biotechnology
OptoVista Holdings, LLC
Washington, DC · CIK 0002036372
Offering snapshot reported Sep 25, 2026 · SEC filing
- Reported sold
- $3.73M Offering amount: $3.73M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 11, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 25, 2026 | Initial | $3,727,518 | No comparison | 7 | SEC filing |
| Sep 6, 2024 | Initial | $6,978,813 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06c
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-598840
Source: Form D, filed Sep 25, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alexander Bailey | Director, Executive |
| Christina Ohnsman | Executive |
| Steven Oliveira | Director |
| Kerry Propper | Director |
| Matthew Michael Rosini | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
C/O Tern Therapeutics, 1200 G Street, Nw Suite 800
Washington, DC, 20005
Washington, DC, 20005